Pharma News

Researchers at Indian Institute of Technology (IIT)-Indore have found that piperine, a natural alkaloid present in black pepper, can be used as a therapeutic agent against neurodegenerative disorder, Fragile X-associated tremor/ataxia syndrome (FXTAS). 

The U.S. Food and Drug Administration is warning patients and health care providers that certain Medtronic MiniMed insulin pumps are being recalled due to potential cybersecurity risks and recommends that patients using these models switch their insulin pump to models that are better equipped to protect against these potential risks. To date, the FDA is not aware of any confirmed reports of patient harm related to these potential cybersecurity risks.

Elevated blood pressure in the first trimester of pregnancy, or an increase in blood pressure between the first and second trimesters, raises the chances of a high blood pressure disorder of pregnancy, according to a study funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health.

Bioactive adhesive tissue patches are emerging as an alternative to suturing for deep cuts and wounds. Collagen-based adhesive gels are commonly used, but these patches are expensive and may cause an immune reaction as collagen is derived from animal sources.

According to the report by Transparency Market Research, the global active pharmaceutical ingredients market is projected to worth approximately US$257.5 bn by the end of 2026. It is noticeable that the market valued nearly US$160.0 bn during 2017. This means that the market is expected to witness the growth with staggering 5.4% CAGR from 2018 to 2026.

C4X Discovery Holdings plc a pioneering drug discovery company, entered into a collaboration with PhoreMost, a UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets. The collaboration, focused initially in Parkinson’s Disease, will combine both company’s technology platforms.

Conatus Pharmaceuticals Inc announced that top-line results from the company’s ENCORE-LF clinical trial of emricasan did not meet its primary endpoint and the company is discontinuing further treatment of patients enrolled in the ENCORE-LF clinical trial.  Also, results from the 24-week extension in the company’s ENCORE-PH clinical trial of emricasan were consistent with results from the initial 24-week treatment period and did not meet predefined objectives. Conatus will continue to work with its partner Novartis on ensuring that all remaining obligations related to the emricasan program are fulfilled.

A Washington State University research team has developed a drug delivery system using curcumin, the main ingredient in the spice turmeric, that successfully inhibits bone cancer cells while promoting growth of healthy bone cells.